# Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

> **NCT04148742** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Dizal Pharmaceuticals**

## Conditions studied

- Non-Hodgkin's B-cell Lymphoma

## Interventions

- **DRUG:** DZD9008

## Key facts

- **NCT ID:** NCT04148742
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08
- **Primary completion:** 2023-07
- **Final completion:** 2023-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Clinical development strategy adjustment, non-safety reason
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04148742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04148742, "Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04148742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*